[Thrombocyte substitution in acute leukemia. Effect of histocompatibility on the clinical efficacy].
Thrombocyte substitution is an essential prerequisite for intensive cytoreductive therapy in acute leukemia. Evaluating 228 thrombocyte transfusions in 17 patients shows that the clinical effectiveness of thrombocyte concentrates can be increased by making the coordination of HLA antigens of donor and receiver as good as possible. When measured in the corrected increment (CI) 24 hours after transfusion, the effectiveness of A3/B1 match preparations (CI = 7.0 +/- 1.6) is significantly higher than that of random preparations (CI = 3.0 +/- 0.5). With the presence of HLA antibodies an effective substitution (CI24 greater than or equal to 4.5) can only be achieved by A3/B1 match thrombocytes. This can only be realized by applying the fourfold thrombapheresis of single donors.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000276:immunology; D001803:Blood Transfusion; D006680:HLA Antigens; D006648:Histocompatibility; D006801:Humans; D007945:Leukemia, Lymphoid / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008875:Middle Aged; D017713:Platelet Transfusion
D006680:HLA Antigens
Thrombozytensubstitution bei akuter Leukämie. Einfluss der Histokompatibilität auf die klinische Wirksamkeit.